ADMA BIOLOGICS INC (ADMA) competitors & alternatives
Health Care · NASDAQ
ADMA BIOLOGICS INC (ADMA)'s top competitors and alternatives — its most similar public companies — include INDIVIOR PHARMACEUTICALS INC (INDV), Repligen (RGEN), ETON PHARMACEUTCIALS INC (ETON), COLLEGIUM PHARMACEUTICAL INC (COLL), Jazz Pharmaceuticals (JAZZ), PAYSIGN INC (PAYS), HAEMONETICS CORP (HAE), MIMEDX GROUP INC (MDXG), SAB BIOTHERAPEUTICS INC (SABS), Regeneron Pharmaceuticals (REGN), Bristol Myers Squibb (BMY) and Pfizer (PFE). These are ADMA BIOLOGICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ADMA competitors & alternatives
-
INDIVIOR PHARMACEUTICALS INCINDVHealth Care
Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions,…
$40.45 (as of 2026-07-22) · market cap $4.9B
-
RepligenRGENHealth Care
Repligen provides critical, high-efficiency bioprocessing technologies and systems that enable biopharmaceutical companies to manufacture life-saving…
$140.09 (as of 2026-07-22) · market cap $7.9B
-
ETON PHARMACEUTCIALS INCETONHealth Care
Eton Pharmaceuticals develops and commercializes rare disease treatments, with a portfolio of ten marketed products and four late-stage candidates targeting…
$43.58 (as of 2026-07-22) · market cap $1.2B
-
COLLEGIUM PHARMACEUTICAL INCCOLLHealth Care
A specialty pharma company building a diversified pain and ADHD portfolio through branded products and acquisitions, though facing material generic headwinds…
$34.72 (as of 2026-07-22) · market cap $1.1B
-
Jazz PharmaceuticalsJAZZHealth Care
A rare-disease biopharmaceutical company with diversified marketed therapies in epilepsy, sleep disorders, and oncology, and an expanding pipeline of…
$250.41 (as of 2026-07-22) · market cap $16.0B
-
PAYSIGN INCPAYSFinancials
Paysign operates a vertically integrated fintech platform delivering prepaid card solutions and processing services to corporate, consumer, and government…
$8.96 (as of 2026-07-22) · market cap $497M
-
HAEMONETICS CORPHAEHealth Care
Haemonetics provides automated plasma collection systems, blood processing devices, and hospital blood management technologies serving plasma centers, blood…
$78.03 (as of 2026-07-22) · market cap $3.5B
-
MIMEDX GROUP INCMDXGHealth Care
MiMedx develops and distributes advanced wound care biologics including human placental allografts and expanding xenograft/collagen products to treat chronic…
$4.17 (as of 2026-07-22) · market cap $621M
-
SAB BIOTHERAPEUTICS INCSABSHealth Care
SAB Biotherapeutics produces fully human polyclonal antibodies via engineered cattle to treat autoimmune diseases, with SAB-142 in Phase 2b trials for type 1…
$3.58 (as of 2026-07-22) · market cap $278M
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
Bristol Myers SquibbBMYHealth Care
Bristol Myers Squibb is a leading biopharmaceutical company specializing in advanced oncology, immunology, and cardiovascular therapies using diverse…
$60.76 (as of 2026-07-22) · market cap $124.9B
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
Not quite? Describe exactly what you want →
Peers are ADMA BIOLOGICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: ADMA BIOLOGICS INC (ADMA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.